BioTime's OncoCyte raises $10m for cancer Dx and therapeutics
This article was originally published in Clinica
Executive Summary
Regenerative medicine company BioTime’s majority-owned subsidiary, OncoCyte Corporation, has received $10m in a new round of equity financing to fund expansion of its development of proprietary diagnostics and therapeutics for cancer in humans.